ReCell Placement and Medical Procedure Overview

Financial Performance Operating Loss, $M Gross Margin, % Revenue, $M 4.0 3.0 2.0 1.0 0.0 2007 2008 2009 2010 100% 75% 50% 25% 0% -25% 2007 2008 2009 2010 0 -5 -10 -15 -20 Increase sales revenues in high value markets ReCell® represented approximately 30% of total sales in Q3 FY11 (total Q3 sales of c.$950k) Increased 73% over previous Q2 FY11 Implement "continuous improvement" models to operations Tighten management of working capital 20 medical avita

View entire presentation